Abvc Biopharma (ABVC) Research & Development (2015 - 2026)
Abvc Biopharma's (ABVC) quarterly Research & Development came in at $33100.0 in Q1 2026, up 14.69% YoY from $28861.0 in Q1 2025, and up 13.91% on a QoQ basis from $29058.0 in Q4 2025.
Abvc Biopharma (ABVC) Research & Development (2015 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 12 years of Research & Development data on file, last reported at $33100.0 in Q1 2026.
- Quarterly Research & Development rose 14.69% year-over-year to $33100.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125324.0 (down 9.88% YoY) and the FY2025 annual result came in at $121085.0, down 32.46% from the prior year.
- Research & Development rose to $33100.0 in Q1 2026, from $29058.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.5 million in Q4 2022 to a low of $28861.0 in Q1 2025.
- A 5-year average of $240578.2 and a median of $69066.0 in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 474.89% — and 2023, when it tumbled 95.17%.
- Tracing ABVC's Research & Development over 5 years: stood at $1.5 million in 2022, then plunged by 95.17% to $72185.0 in 2023, then plunged by 55.7% to $31980.0 in 2024, then decreased by 9.14% to $29058.0 in 2025, then climbed by 13.91% to $33100.0 in 2026.
- The last three Research & Development figures came in at $33100.0 (Q1 2026), $29058.0 (Q4 2025), and $29890.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | 22,707.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22,707.00 |
| Mar 31, 2026 | 33,100.00 |
| Dec 31, 2025 | 29,058.00 |
| Sep 30, 2025 | 29,890.00 |
| Jun 30, 2025 | 33,276.00 |
| Mar 31, 2025 | 28,861.00 |
| Dec 31, 2024 | 31,980.00 |
| Sep 30, 2024 | 37,825.00 |
| Jun 30, 2024 | 40,401.00 |
| Mar 31, 2024 | 69,066.00 |
| Dec 31, 2023 | 72,185.00 |
| Sep 30, 2023 | 141,310.00 |
| Jun 30, 2023 | 514,442.00 |
| Mar 31, 2023 | 334,979.00 |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | 305,483.00 |
| Jun 30, 2022 | 532,782.00 |
| Mar 31, 2022 | 359,404.00 |
| Dec 31, 2021 | 260,188.00 |
| Sep 30, 2021 | 263,424.00 |